| 查看: 346 | 回复: 1 | |||
| 当前主题已经存档。 | |||
abcd888898银虫 (正式写手)
|
[交流]
【转帖】Novo Nordisk receives approval for Victoza® in Japan
|
||
|
Novo Nordisk receives approval for Victoza® in Japan (20 January 2010) Read in PDF format Novo Nordisk receives approval for Victoza® in Japan Novo Nordisk today announced that the Japanese Ministry of Health, Labour and Welfare has approved Victoza® for the treatment of type 2 diabetes. Victoza® is the brand name for liraglutide, the first Glucagon-Like Peptide-1 (GLP-1) analogue approved in Japan, developed for the treatment of type 2 diabetes. Victoza® is indicated as monotherapy or as an add-on to sulphonylurea (SU) in people with type 2 diabetes. "The Japanese approval of Victoza® represents a major advancement in the treatment of type 2 diabetes and an important milestone for Novo Nordisk." says Mads Krogsgaard Thomsen, executive vice president and chief science officer of Novo Nordisk. "We are excited to pioneer the GLP-1 market in Japan, where we are convinced Victoza® will prove to be a valuable treatment option for people with type 2 diabetes. The clinical studies conducted in Japan showed Victoza® to provide superior glucose control with a low risk of hypoglycaemia." Novo Nordisk expects to launch Victoza® in Japan in the first half of 2010 upon completion of price negotiations. |
回复此楼» 猜你喜欢
中药检测种决明子、枳实、水蛭、茯苓品种检测问题交流
已经有1人回复
-
天平合规性问题
已经有113人回复
-
药物学论文润色/翻译怎么收费?
已经有207人回复
-
考博求助
已经有2人回复
-
基金评委应该全面采取AI，完美规避人情因素的干扰
已经有2人回复
-
招聘材料计算，分子动力学模拟合作讲师
已经有10人回复
-
招聘材料计算，分子动力学模拟相关讲师
已经有13人回复
-
25金币微谱求助，谢谢
已经有1人回复
-
考博
已经有1人回复
-
考博求博导收留
已经有0人回复
-
跪求SIMCA14 安装包
已经有0人回复
2楼2010-01-20 20:07:57